Role of Lysosomal Gene Variants in Modulating GBA‐Associated Parkinson's Disease Risk

• Published in: Movement disorders Vol. 37; no. 6; pp. 1202 - 1210
• Main Authors: Straniero, Letizia, Rimoldi, Valeria, Monfrini, Edoardo, Bonvegna, Salvatore, Melistaccio, Giada, Lake, Julie, Soldà, Giulia, Aureli, Massimo, Shankaracharya, Keagle, Pamela, Foroud, Tatiana, Landers, John E., Blauwendraat, Cornelis, Zecchinelli, Anna, Cilia, Roberto, Di Fonzo, Alessio, Pezzoli, Gianni, Duga, Stefano, Asselta, Rosanna
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.06.2022; Wiley Subscription Services, Inc
• Subjects: Clinical trials; Genes; Genomes; Glucosylceramidase; Glucosylceramidase - genetics; Heterozygote; Humans; Lysosomal storage diseases; Lysosomes; Meta-analysis; Movement disorders; Mucopolysaccharidosis; Mutation; Neurodegeneration; Neurodegenerative diseases; Parkinson Disease - complications; Parkinson Disease - genetics; Parkinson's disease; Parkinson's disease; GBA; lysosomal genes; mutation burden; Regular Issue; Replication; Statistical analysis; Parkinson's disease; GBA; lysosomal genes; mutation burden
• ISSN: 0885-3185; 1531-8257
• DOI: 10.1002/mds.28987

Background To date, variants in the GBA gene represent the most frequent large‐effect genetic factor associated with Parkinson's disease (PD). However, the reason why individuals with the same GBA variant may or may not develop neurodegeneration and PD is still unclear. Objectives Therefore, we evaluated the contribution of rare variants in genes responsible for lysosomal storage disorders (LSDs) to GBA‐PD risk, comparing the burden of deleterious variants in LSD genes in PD patients versus asymptomatic subjects, all carriers of deleterious variants in GBA. Methods We used a custom next‐generation sequencing panel, including 50 LSD genes, to screen 305 patients and 207 controls (discovery cohort). Replication and meta‐analysis were performed in two replication cohorts of GBA‐variant carriers, of 250 patients and 287 controls, for whom exome or genome data were available. Results Statistical analysis in the discovery cohort revealed a significantly increased burden of deleterious variants in LSD genes in patients (P = 0.0029). Moreover, our analyses evidenced that the two strongest modifiers of GBA penetrance are a second variation in GBA (5.6% vs. 1.4%, P = 0.023) and variants in genes causing mucopolysaccharidoses (6.9% vs. 1%, P = 0.0020). These results were confirmed in the meta‐analysis, where we observed pooled odds ratios of 1.42 (95% confidence interval [CI] = 1.10–1.83, P = 0.0063), 4.36 (95% CI = 2.02–9.45, P = 0.00019), and 1.83 (95% CI = 1.04–3.22, P = 0.038) for variants in LSD genes, GBA, and mucopolysaccharidosis genes, respectively. Conclusion The identification of genetic lesions in lysosomal genes increasing PD risk may have important implications in terms of patient stratification for future therapeutic trials. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.